Chemo-radiotherapy is standard treatment of stage IIIA-N2 bulky or IIIB non-small cell lung cancer (NSCLC). Surgical resection of residual disease in downstaged patients may improve overall survival. In this setting, restaging disease is still a challenge. 18 F-FDG PET/CT represents the gold standard although accuracy results are disappointing. Endoscopic bronchial/ esophageal ultrasound (EBUS/EUS)-guided fine needle aspiration (FNA) may confirm lymph node (LN) involvement. We analyzed 16 patients with stage IIIA-N2 bulky or IIIB NSCLC treated with chemo-radiotherapy. At restaging, all patients performed EBUS/EUS with FNA and PET/CT scan and results were compared. Patients underwent PET/CT scan 43 days (range: 24-89) and EBUS/EUS 42 days (range: 14-71) after therapy. Overall, 7 EBUS and 9 EUS procedures were performed: no complications resulting from the procedure occurred. In 6 patients EBUS/EUS did not reveal any suspicious lesions; in 2 the exam showed enlarged mediastinal LN that were biopsied, but with no evidence of tumor cells; in 2 the sample was not considered diagnostic; 6 had persistent mediastinal LN involvement. PET/CT scan showed 4 cases of complete metabolic response, 9 partial metabolic response, 2 stable metabolic disease and one progressive metabolic disease. Notably, all 7 patients with .80% decrease in SUV with respect to basal value showed a pathological complete response or negative EBUS/EUS. EBUS/EUS could be used to complement PET/CT scanning to verify mediastinal LN clearance. Further prospective trials are warranted to confirm the utility of EBUS/EUS together with PET/CT in restaging locally advanced NSCLC.
Introduction
Clearance of mediastinal lymph node (LN) metastases is the most important prognostic factor in the prediction of longterm survivors after chemo-radiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) (1) (2) (3) . To date, the most effective strategy for cleaning mediastinal LN from metastasis seems to be the administration of chemotherapy concomitantly with radiotherapy (4, 5) .
In terms of results, curative chemo-radiotherapy is considered the treatment of choice in cases of locally advanced disease for bulky involvement of ipsi-or contro-lateral mediastinal LN, mediastinal infiltration or a reduced cardiorespiratory reserve that contraindicates surgical intervention. In this setting, several trials have shown that curative radiotherapy produces the same results in terms of survival as those obtained by surgery (6) (7) (8) . Sequential chemotherapy and 3-dimensional hypofractionated accelerated radiotherapy (3D-HAR) has also produced interesting results with respect to local disease control and safety profile (9) . Recently, prospective studies that explored the role of surgery after chemoradiotherapy have shown an improvement in survival as the result of adopting a trimodality approach in patients where a mediastinal LN downstaging was documented after the completion of concomitant induction therapy (8, 9) . Mediastinal restaging after chemo-radiotherapy in this setting is still a challenge. In fact invasive procedures such as mediastinoscopy give incomplete results in about half of all patients due to the presence of diffuse fibrosis (10) . The 18 F-FDG PET/ CT scan is a non-invasive exam with high specificity but low sensitivity (11, 12) and this is due to the disagreement regarding the timing of the 18 F-FDG PET/CT scan for the response evaluation. Theoretically, early restaging after chemoradiotherapy may produce an overestimated 18 F-FDG uptake due to the presence of an inflammatory process, whereas restaging that is performed too late may be less suitable for the repopulation of the tumor.
Nevertheless, a pathological confirmation of mediastinal LN is needed in order to select patients with a better prognosis who may benefit from the surgical resection of the residual disease. Endoscopic techniques can provide material for cytopathologic analysis through fine needle aspirations (FNA). Hence, they can be performed under the guidance of linear ultrasound bronchoscopes (EBUS) or esophagealscopes (EUS) in the staging of mediastinum in patients without prior treatment (13) . Recently, EBUS has been used when restaging the upper mediastinum after induction chemotherapy in patients with stage IIIA NSCLC, with a sensitivity ranging from 72% to 76%, a specificity of between 86% and 100% and an accuracy rate ranging from 77% to 84% (14, 15) . Also, EUS is feasible for LN restaging after induction treatment, in particular for the stations in the lower mediastinum and aortic-pulmonary window, as confirmed by two small series where the technique showed a level of diagnostic accuracy ranging from 86% to 92% (16, 17) .
We performed mono-institutional prospective pilot series on patients with locally advanced NSCLC for biopsy proved mediastinal LN involvement in order to verify the compliance with the mini-invasive EBUS/EUS procedures and verify the correspondence between this procedure and 18 F-FDG PET/CT scan at restaging following the conclusion of chemo-radiotherapy treatment.
Patients and Methods

Patient Selection
We prospectively collected all the clinical data of stage III NSCLC patients for histological mediastinal N2 or N3 involvement or mediastinal infiltration from May 2007 to September 2011.
After performing a CT scan and an integrated 18 F-FDG PET/ CT scan at staging, patients received platin-based induction chemotherapy followed by 3-dimensional hypofractionated accelerated radiotherapy (3D-HAR) using helical tomotherapy. When the treatment was completed, patients performed restaging with an integrated 18 F-FDG PET/CT scan and EBUS/EUS-FNA. Overall, 16 patients were eligible for the analysis, all of whom gave their consent required for all the diagnostic and therapeutic procedures involved.
Endoscopic Ultrasound and Pathologic Analysis
EBUS and EUS had been performed with Olympus ultrasound endoscopes (BF-UC160F for EBUS and GF-UCT160 for EUS) and with an EXERA EU-C60 echo-processor. The technique used was chosen based on the node station to biopsy. The procedures were performed under deep sedation with propofol and renifentanyl using a rigid bronchoscope in case of bronchial examination. Transbronchial needle aspiration (TBNA) or FNA was performed with Olympus 22G needles (NA-201SX-4022 for TBNA and NA-200H-8022 for FNA). For each nodal site, 5-8 passes were performed for cytologic and cytohistologic examination. The samples were considered suitable when lymphocytes were found during a rapid on site examination (ROSE).
Imaging
All patients were submitted to a combined PET/CT in-line system (Biograph Sensation 16 Siemens). Patients were instructed to fast for at least 6 h prior to scanning, which started 50-60 min after the injection of a standard dose of 5.18 MBq 18 F-FDG per kilogram. The glucose level was measured before the injection of the radiotracer and if this proved greater than 160 mg/dL, the exam was delayed. A non-enhanced low-dose CT scan during shallow breathing (80 mA, 120 kV parameters) was performed, followed by a PET scan (3 min per bed, 3D acquisition). The scan covered the area from the head to the upper thighs with the patient in a supine position. The acquired images were reconstructed using a standard 3D-iterative ordered subset expectation maximization (OSEM) algorithm.
We performed a qualitative analysis by visually examining all the images and then a semi-quantitative evaluation to measure the uptake of the radiotracer in the defined volume of interest (VOI) expressed by SUV. The metabolic response was scored according to criteria proposed by the European organization for research and treatment of cancer (EORTC) (18) . Progressive metabolic disease (PMD) was classified as a 25% increase in FDG uptake compared to the baseline. Stable metabolic disease (SMD) was classified as an increase in FDG uptake of less than 25%, or a decrease of less than 15%. Partial metabolic response (PMR) was classified as a reduction of more than 25%. Complete metabolic response (CMR) was classified as a complete reduction of FDG uptake. The response was judged as down-staged if there was at least a partial metabolic response in the metastatic LN.
Treatments
All patients underwent induction chemotherapy based on platin containing regimen (carboplatin or cisplatin) combined with a third generation drug (such as docetaxel, gemcitabine and paclitaxel) for two to four courses. Afterwards, all patients performed 3D-HAR using tomotherapy. The dose prescription for the gross tumor volume (GTV) was 30 Gy in 5 daily fractions at the reference isodose (60-70%); the dose prescription for LN volume was 25 Gy in 5 daily fractions at the reference isodose.
Restaging
Restaging procedures were performed at least 2 weeks after the completion of the chemo-radiotherapy treatment, and involved an integrated 18 F-FDG PET/CT scan and outpatient EBUS/EUS FNA. The same mediastinal LN stations found to be positive during the initial analysis were approached again for TBNA or FNA at restaging. If restaging with EBUS/ EUS FNA showed no suspected mediastinal LN, or in cases where biopsied LN were present with no tumor cells, patients were considered as down-staged. In patients with an adequate cardio-pulmonary reserve without mediastinal infiltration, therapy proceeded with a thoracotomy including a lobespecific mediastinal LN dissection. During thoracotomy LN resection, was performed for Naruke 4, 7, 10 and 11 for right upper lobe lobectomy (19) . When possible, Naruke 2 was resected as well. For the lower lobe lobectomy Naruke 7-11 were taken. As much LN tissue as possible was resected en bloc with the pulmonary resection.
Statistical Analysis
The results of the EBUS/EUS restaging were compared with those of the PET/CT restaging. A negative result from the PET/CT restaging was defined as a complete or partial response, and a positive result was defined as a stable or progressive disease. PET/CT restaging was considered as a gold standard for the calculation of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of EBUS/EUS restaging. The kappa value was calculated to assess the level of correspondence between the two series of results which exceeded the chance level of correspondence. Progression-free survival (PFS) was defined as the interval between the date of the start of treatment and the date of disease progression-or the date of death in the absence of progression-or the date of the last follow-up for live patients who were progression-free at the time of the last follow-up.
Overall survival (OS) was defined as the interval between the date of diagnosis and the date of death from any cause, or the date of the last follow-up for live patients. The PFS and OS probabilities and 95% confidence intervals (95% CI) were computed by the Kaplan-Meier product-limit method and the absolute effect of treatment was assessed by way of a log-rank test. All statistical analyses were performed with SAS (version 9.3, SAS Institute).
Results
Patient Characteristics
Patient characteristics are reported in Table I . The number of nodal sites biopsied during the initial staging procedures was 0-2. All patients received doublet chemotherapy in the form of a platin-based regimen combined with a third generation drug for two or four courses, on the basis of patient compliance and clinical benefit, followed by 3D-HAR tomoradiotherapy. On average, 18 F-FDG PET/CT scan restaging was performed at 43 days (range: 24-89), whereas EBUS/ EUS FNA was performed 42 days (range: 14-71) after the completion of treatment.
Mediastinal Node Restaging
Mediastinal nodes restaging is detailed in were biopsied and an average of two nodal sites were approached. In 6 patients endoscopic restaging did not reveal any suspicious images. In 2 patients the exam showed enlarged mediastinal LN but a biopsy revealed no evidence of tumor cells (one of these was confirmed by a thoracotomy), in 2 patients the samples were not considered diagnostic due to the absence of lymphocytes) and finally in 6 patients there was persistent documented N2-N3 involvement by tumor cells. The presence of lymphocytes in the sample confirms the biopsy of mediastinal LN. Table II shows the pathological and radiological response obtained by each patient.
The restaging 18 F-FDG PET/CT scan identified: 4 patients with CMR, 9 patients with PMR, 2 patients with SMD and finally 1 patient with PMD. Notably, 7 (78%) of the 9 patients with a decrease in SUV exceeding 80% of the basal value had mediastinal LN clearance documented by a negative EBUS/ EUS or by the absence of tumor cells in the biopsy, including one patient who underwent a left pneumonectomy and mediastinal LN resection: overall, 37 nodes were removed and no tumor invasion was found, as previously showed by EUS. The comparison between the results of the EBUS/EUS restaging versus those of the PET/CT restaging are summarized in Table III . EBUS/EUS restaging had a sensitivity of 50% (2/4), a specificity of 60% (6/10), a NPV of 75% (6/8) and a PPV of 33% (2/6). The kappa value for the level of correspondence between the two series of results was 0.09 (p 5 0.73).
Follow-up
At the median follow-up of 45 months (range 7.8-47.8), the median OS and PFS were respectively 31 (95% CI 13.9-not reached) and 9 (95% CI 4.8-18.5) months. 
Discussion
Today the treatment of choice in stage IIIA-N2 bulky or IIIB NSCLC is curative concomitant chemo-radiotherapy. However, in recent clinical experiences, the addition of surgery seems to enhance OS in patients with clearance of mediastinal LN metastases (8, 9) . This provides a strong rationale for identifying the most accurate restaging technique; moreover, clinical response evaluation after completion of induction or definitive treatment is still a challenge in clinical practice. Four weeks after chemotherapy, patients had remediastinoscopy: in 40% of patients the procedure was interrupted or switched to thoracotomy due to extensive adhesions and fibrosis.
Hence, in attempting to achieve a complete radical resection of primary tumor and mediastinal LN dissection, 73% of patients experienced a prolonged period of hospitalization due to post-operative complications. The overall sensitivity, specificity and accuracy of re-mediastinoscopy were 29%, 100% and 60% respectively in comparison to the values of 77%, 92% and 83% produced by 18 F-FDG PET/CT. Following this trial, 18 F-FDG PET/CT becomes the gold standard in restaging of stage III-NSCLC.
In order to facilitate the recognition of patients with metabolic response and clearance of mediastinal metastases, many authors have tried to find a surrogate index that can be obtained from nuclear examination. Cerfoglio and colleagues (5, 12) affirmed that a decrease in SUV exceeding 80% is indicative for a metabolic complete response with the disappearance of LN macroscopic metastasis. Cerfoglio's hypothesis was confirmed by Stigt (17) as well as by our experience: in fact, patients with a reduction in the SUV value of more than 80% had a clearance of LN metastasis. This procedure is limited by the fact that it is impossible to identify the presence of LN micrometastases by performing a nuclear examination.
As a consequence, in order to improve 18 The last evidence reported is that of Shingyoji et al. (22) where the authors utilized EBUS and 18 F-FDG PET/CT to confirm the response to systemic treatments (carboplatin/ gemcitabine, gefitinib) in only two patients with advanced NSCLC: no side effects due to endoscopic procedures were reported, and this is confirmed by our own experience. The authors concluded by affirming that EBUS may help clinicians in the therapeutic algorithm of the patient.
In comparison to Stigt's experience (17) , in our series, the sensitivity and specificity levels of EBUS/EUS restaging toward PET/CT restaging were 50% and 60% respectively, which means that approximately half of the positive (stable/ progressive disease) as well as the negative (partial/complete response) values of the PET/CT restaging results were not confirmed by EBUS/EUS restaging, with an overall PPV of EBUS/EUS lower than 33%.
Hence, the kappa value regarding the correspondence between the two series of results was 0.09, which indicates a level of correspondence no higher that the value that would be expected based on chance alone. As a consequence, our data raise the issue of how to recognize the factors that may explain the lack of coherence between the PET/CT and EBUS/EUS restaging results in stage IIIA-N2 bulky or IIIB NSCLC.
First of all, this may be due to the limited number of patients analyzed: in fact, all the above-mentioned clinical experiences, including our own, involved a limited number of patients. This could be justified by the fact that EBUS/EUS are techniques which have only recently begun to spread and emerge in daily clinical practice.
Hence, for EBUS/EUS restaging, there are potential factors associated to an inaccuracy in the locally advanced NSCLC restaging. For example, we observed that station 7 always involved disagreement lack of coherence between positive EBUS/EUS and negative PET/CT restaging, and that stations 4L and 4R were always involved in the opposite pattern of disagreement. This might be interpreted as suggesting that certain stations are more difficult to evaluate with either EBUS/EUS or PET/CT or, alternatively, that the misleading effect of necrosis and fibrosis on the accuracy of either technique is unevenly distributed across the stations.
Regarding PET/CT, some factors which may have caused this inaccuracy are tumor necrosis, which could cause falsepositive scans, and small-sized tumor foci, which could yield false-negative scans (11) .
Hence, our evidence is limited by the interpretation of the LN change due to the fact that CT image collections were obtained with a non-enhanced low dose CT scan during shallow breathing. In the above-mentioned clinical trials (12, 17, 20, 21) , all the authors carried out nuclear and radiological exams where each patient had 18 F-FDG and iodine contrast in the same session. This is rarely the case in daily clinical practice given that, to date, there are no data which support routine programming of this examination in order to increase diagnostic accuracy.
Conclusions
Our pilot experience confirms the good tolerance level of EBUS/EUS restaging after chemotherapy and radiotherapy for locally advanced NSCLC. However, the availability of LN samples for restaging in only 3 of the 9 patients analyzed does not permit any conclusions to be drawn about the concordance between the pathological response and SUV decrease .80%. Further large prospective randomized trials are warranted to confirm whether the relief achieved as a result of these endoscopic procedures is complementary to those gained through 18 F-FDG PET/CT and so confirm the metabolic response and stratify patients with good or worse prognoses.
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